石药集团:PCSK9 siRNA启动III期临床

细胞基因治疗前沿
Feb 28

注:本文不构成任何投资意见和建议,以官方/公司公告为准;本文仅作医疗健康相关药物介绍,非治疗方案推荐(若涉及),不代表平台立场。任何文章转载需得到授权。近日,石药集团在中国药物临床试验登记与信息公示平台连续登记了两项SYH2053注射液的国内III期临床试验,旨在评估该药单药治疗原发性高胆固醇血症(非家族性)和混合型血脂异常的有效性和安全性。SYH2053是石药集团自主研发的靶向PCSK9的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10